CP 003
Alternative Names: CP003Latest Information Update: 28 Feb 2021
Price :
$50 *
At a glance
- Originator Caelus Health
- Developer Caelus Health; Johnson & Johnson Innovation
- Class Antihyperglycaemics; Diabetes mellitus vaccines
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Type 2 diabetes mellitus
Most Recent Events
- 28 Feb 2021 No recent reports of development identified for preclinical development in Type-2-diabetes-mellitus(Prevention) in Netherlands
- 05 Jan 2017 Caelus Health enters into a collaboration with Johnson & Johnson Innovation for the development of CP-003
- 05 Jan 2017 Preclinical trials in Type-2 diabetes mellitus (Prevention) in Netherlands (unspecified route)